Contemporary Management of Coronary Artery Fistulas Associated With Coronary Artery Aneurysms Authors: Neel Koyawala, Krishna Santosh Vemuri, Amit Hooda Published: 2026 ABSTRACT Corresponding Author The case presented by Okuno et al1 in this issue of JACC: Case Reports highlights a challenging and rare situation requiring transcatheter management of an acute rupture of coronary aneurysm in a patient with cirrhosis and coronary-to-pulmonary artery fistulas. According to the Coronary Artery Aneurysm Registry, coronary artery aneurysms (CAAs) are uncommon, occurring in less than 1% of the general population. They exhibit a strong male predominance and are most frequently located in proximal coronary segments.2 Defined as focal dilation greater than 1.5 times the diameter of the adjacent normal coronary segment, CAAs are often diagnosed incidentally on coronary angiography or coronary computed tomography angiography. CAAs can be described as saccular (transverse greater than longitudinal diameter), fusiform (longitudinal greater than transverse diameter), and giant (>20 mm). The right coronary artery is affected most frequently (∼40%), followed by the left anterior descending artery (∼32%). Mechanistically, atherosclerosis and/or an inflammatory process lead to weakening of the tunica media. The most common causes of CAAs are atherosclerosis in adults and Kawasaki disease in children. Other causes may include vasculitis, connective tissue disorders, infections, and congenital abnormalities.2 Coronary fistulas are present in approximately 0.002% of the general population and 0.1% to 0.5% of patients undergoing coronary angiography.3,4 Many patients with coronary fistulas (ie, ≤80%) have associated coronary aneurysms.5 Coronary fistulas result in a high-volume flow through low-resistance shunting, thereby increasing wall stress and promoting development of aneurysms independent of coronary atherosclerosis. They most commonly originate in the left anterior descending artery and terminate in the pulmonary artery. Although many patients with coronary-to-pulmonary artery fistulas remain asymptomatic, those with a greater number of fistulas and larger fistula diameters are more likely to experience dyspnea and chest pain, presumably from the coronary steal phenomenon. To our knowledge, there are currently no randomized clinical trials to guide the management of patients with CAAs. Medical therapy for isolated CAAs generally focuses on aggressive cardiovascular risk factor modification and antithrombotic therapy, including dual antiplatelet therapy and, in selected patients with large aneurysms, consideration of systemic anticoagulation. In stable patients with CAAs, indications for intervention are not well defined. Factors favoring procedural management include giant aneurysm size, left main involvement, rapid enlargement, thrombus, pseudoaneurysm formation, and inducible ischemia. Percutaneous options include covered stent grafts and stent-assisted coil or plug embolization, whereas surgical repair with coronary artery bypass grafting is generally reserved for giant aneurysms, left main disease, multivessel involvement, major side-branch involvement, or failed percutaneous therapy.2 In patients presenting with acute coronary syndrome, the priority is prompt restoration of coronary flow, often by thrombectomy and using intracoronary glycoprotein IIb/IIIa inhibitors. Stent implantation should be individualized given the elevated risk for complications in aneurysmal vessels, including stent thrombosis rates approaching 15% at 1 year.2 Management of coronary artery fistulas (CAFs) is guided by the presence of symptoms or myocardial ischemia, as well as the size and anatomy of the fistula and any associated aneurysms. Small, asymptomatic fistulas—typically defined as those with a diameter less than or equal to that of the native vessel—can be managed conservatively with periodic imaging surveillance because spontaneous closure has been reported in some cases. In contrast, large CAFs are generally recommended for procedural closure because of the risk for progressive enlargement and associated complications. Some experts also advocate for closure of medium-sized fistulas before further dilation occurs and intervention becomes more challenging. Transcatheter therapy can be performed successfully using coil embolization or vascular plug devices.6 However, for patients with large associated aneurysms, multiple fistulas, dilated proximal segments (>10 mm), or anatomy that is not amenable to transcatheter intervention, surgical management may be preferred. A major concern after fistula closure, regardless of the treatment strategy, is thrombosis within the dilated proximal coronary segment due to persistent low-flow conditions, which may result in myocardial infarction.3 To mitigate this risk, surgical closure combined with concomitant bypass grafting and subsequent indefinite oral anticoagulation has been recommended for patients with distal CAFs and large proximal aneurysms (>10 mm). The risk for postprocedural thrombosis may also be reduced by intervening earlier in the disease course, when the fistula is of moderate size and the proximal coronary artery has not yet undergone significant dilation.7 Transcatheter closure of CAFs requires a range of specialized equipment, including 6- to 8-F guiding catheters, guide catheter extension systems, 125-cm-long diagnostic catheters for telescoping techniques, and guidewires. Typically, 0.014-inch coronary guidewires are used for smaller fistulas, whereas 0.035-inch guidewires are preferred for larger channels. Microcatheters (2.4-2.9 F) facilitate the delivery of embolization coils, whereas deflectable sheaths, such as the small- or medium-curve Agilis sheath (Abbott Vascular), and hydrophilic braided sheaths, including the Flexor Shuttle sheath (Cook Medical) and Destination sheath (Terumo), are commonly used for vascular plug deployment. The most frequently used vascular plugs are the Amplatzer Vascular Plug II and IV. Plugs are particularly well suited for larger fistulas because they can be repositioned before release and promote rapid thrombosis. In contrast, pushable and detachable coils are generally preferred for smaller, tortuous fistulas and coronary perforations, although multiple coils are often required to achieve complete occlusion. Covered stent grafts, such as the Graftmaster (Abbott Vascular) and PK Papyrus (Biotronik), are used infrequently because of their relatively high risk for thrombosis. Their use is typically reserved for select cases in which other transcatheter options are not feasible, such as complex plexiform fistulas with multiple origins. Transcatheter closure of CAFs is associated with high procedural success rates, ranging from 80% to 100%.7 Despite these favorable outcomes, the procedure carries significant risks, including vessel injury, such as coronary dissection or rupture, device embolization of coils or vascular plugs, thrombosis with subsequent myocardial infarction, cardiac arrhythmias, and fistula recanalization requiring repeat intervention. Ruptured CAAs associated with a fistula remain a rare clinical entity. Management should involve evaluation by a comprehensive multidisciplinary heart team, considering patient preferences, comorbidities, and procedural risk. Transcatheter closure offers a minimally invasive alternative for selected high-risk patients, as demonstrated by Okuno et al1 in a patient with cirrhosis who was considered a poor candidate for surgical intervention. Continued advances in cardiac imaging and 3-dimensional modeling may further enhance preprocedural planning, facilitate optimal device selection, and improve the likelihood of successful transcatheter closure. Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose.